The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 

A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis.

A multicenter double-blind study was carried out in patients with rheumatoid arthritis ( RA) by comparing treatment with a novel immunomodulator, lobenzarit, disodium 4-chloro-2, 2'-iminodibenzoate, with an inert placebo. Both groups of patients received 75 mg/day of indomethacin as a basal regimen during the study period of 16 weeks. Group 1 (115 patients) received 240 mg/day lobenzarit, 80 mg TID, and Group 2 (115 patients) received placebo TID orally. A statistically significant improvement was noted in the number of swollen joints and in the Lansbury index at Weeks 12 and 16 in Group 1 as compared to Group 2. Overall clinical effectiveness was significantly higher in Group 1 (63%) than in Group 2 (43%). Incidence of side effects was 38% in Group 1 and 22% in Group 2. The most frequent side effect in both groups was gastrointestinal upset. Our data confirm that lobenzarit is a useful agent in the treatment of patients with RA.[1]

References

  1. A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. Shiokawa, Y., Horiuchi, Y., Mizushima, Y., Kageyama, T., Shichikawa, K., Ofuji, T., Honma, M., Yoshizawa, H., Abe, C., Ogawa, N. J. Rheumatol. (1984) [Pubmed]
 
WikiGenes - Universities